.gif)
Clore Laboratory: News
Diabetes, Obesity and Metabolic Research
14 March 2005 – Dipeptidyl peptidase inhibitor improves glucose tolerance in diabetes model
Results of a collaborative study on the dipeptidyl peptidase IV inhibitor P32/98 by the Clore Laboratory, University of Buckingham, UK, the Institut für Diabetes ‘Gerhard Katsch’, Karlsburg, Germany, and Probiodrug AG, Halle (Saale), Germany, are published in Diabetes Obesity and Metabolism .
Dipeptidyl peptidase IV inhibitors are promising new oral therapies for the treatment of type 2 diabetes. They act by inhibiting the breakdown of endogenous incretins, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thereby enhancing insulin secretion in response to raised blood glucose.
In the current study in a model of type 2 diabetes, the DPP-IV inhibitor P32/98 elicited a sustained improvement in the glucose tolerance in both prediabetic and diabetic rats, which was similar to those obtained with the insulin sensitiser drug rosiglitazone. However, in contrast to rosiglitazone, P32/98 did not increase weight gain.
The full author list and reference is:
Wargent E, Stocker C, Augstein P, Heinke P, Meyer A, Hoffmann T, Subramanian A, Sennitt MV, Demuth H-U, Arch JRS, Cawthorne MA. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes Obes. Metab. 2005 7(2):170-181. doi:10.1111/j.1463-1326.2004.00383.x